Tirzepatide: A Weight Loss Injectable Drug for Type 2 Diabetes


If you’re managing type 2 diabetes, you might wonder if the new headline-making injectable drugs with weight loss benefits are right for you.

One such drug is tirzepatide (Mounjaro) — a first-in-class GLP-1 and GIP receptor agonist for which stars such as sports legend Charles Barkley (according to a May interview on the Dan Patrick Show), entertainer Rosie O’Donnell (according to a January TikTok video she posted), and Real Housewives of New Jersey star Lauren Manzo (according to a May interview on the Virtual Reali-Tea podcast), credit significant weight loss.

The drug has also been linked to big advantages for people with type 2 diabetes, the condition it is currently approved for treating by the U.S. Food and Drug Administration (FDA).

Tirzepatide has been shown to be more effective in both lowering hemoglobin A1C and weight than a similar headline-grabbing injectable, semaglutide (Ozempic, Wegovy), notes Jacqueline Lonier, MD, an endocrinologist and assistant professor of medicine at Columbia University Irving Medical Center’s Naomi Berrie Diabetes Center in New York City.



Please enter your comment!
Please enter your name here

Stay in Touch

To follow the best weight loss journeys, success stories and inspirational interviews with the industry's top coaches and specialists. Start changing your life today!


Related Articles